Friday, July 31, 2026

Military Challenge: Russia-Backed North Korea Unveils New SLBMs And Radar-Dodging Cruise Missiles

North Korea showcased new SLBMs and supersonic missiles at the Defense Development-2025 exhibition, signaling advanced military capabilities.

GC Biopharma Presents Aggregation Study of Alyglo IVIG… A New Benchmark for Safe Immunotherapy

GC Biopharma USA will present findings on IVIG formulations, highlighting Alyglo's lower protein aggregation and improved stability at NHIA 2026.

Japan Moves Closer to Spot Crypto ETFs as Ruling Party Backs Yen Stablecoin Strategy

Japan's ruling party urges the government to establish a legal framework for a cryptocurrency ETF and promote yen stablecoin development.

Tag: combination therapy

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Samjin Pharm Just Made a Move That Could Shake Up the Alzheimer’s Treatment Market

Samjin Pharmaceutical launches Newtoin Duo Tab, a dual-action Alzheimer’s treatment, enhancing medication adherence for patients.

PharmGen Science Releases Tabapheno Extended-Release for Dyslipidemia Treatment

PharmGen Science launches Tabapheno Extended-Release Tablets for mixed dyslipidemia, enhancing treatment convenience and adherence.

Nesuparib: The Game-Changing Cancer Treatment for Small Cell Lung Cancer Revealed at AACR 2026

Onconic Therapeutics reveals Nesuparib's promising preclinical results for small cell lung cancer, outperforming existing treatments significantly.

New Breakthrough: HER2 Positive Stomach Cancer Treatment with Dual Targeted Therapy Shows 81% Tumor Size Reduction

A study reveals that combining trastuzumab deruxtecan and pertuzumab significantly reduces tumor size in HER2-positive gastric cancer.

Unlocking Treatment Potential: GI-102 and Pasritamig Clinical Trial Insights

GI Innovation has filed an IND application for a clinical trial on a combination therapy for metastatic prostate cancer in South Korea and the U.S.

NCCN Endorses Leclaza and Rybrevant Combo as Top Lung Cancer Treatment: What You Need to Know

NCCN guidelines now classify Leclaza + Rybrevant as a preferred first-line treatment for lung cancer, enhancing patient access and management.

Yuhan’s Leclaza and J&J’s Rybrevant: How This Cancer Combo Surged Past 1 Billion USD in Sales

Sales of Yuhan's lung cancer drug 'Lazertinib' and J&J's 'Amivantamab' exceeded 1 trillion won last year.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.